A deficiency of constitutive nitric oxide synthase (cNOS)-derived nitric oxide (NO), due to reduced availability of L-arginine, importantly contributes to allergen-induced airway hyperresponsiveness (AHR) after the early asthmatic reaction (EAR). Since cNOS and arginase use L-arginine as a common substrate, we hypothesized that increased arginase activity is involved in the allergen-induced NO deficiency and AHR. Using a guinea pig model of allergic asthma, we addressed this hypothesis by examining the effects of the specific arginase inhibitor nor-NOHA on the responsiveness to methacholine of isolated perfused tracheae from unchallenged control animals and from animals 6 h after ovalbumin challenge. Arginase activity in these preparations was investigated by measuring the conversion of L-[ 14 C]arginine to [ 14 C]urea. Airways from allergen-challenged animals showed a 2.0-fold (P<0.001) increase in responsiveness to intraluminal (IL) administration of methacholine compared to controls. A similar hyperresponsiveness (1.8-fold, P<0.01) was observed in control airways incubated with the NOS inhibitor L-NAME (0.1 mM; IL), while L-NAME had no further effect on the airways from challenged animals. Remarkably, 5 µM nor-NOHA (IL) normalized the hyperresponsiveness of challenged airways to basal control (P<0.001), and this effect was fully reversed again by 0.1mM L-NAME (P<0.05). Moreover, arginase activity in homogenates of the hyperresponsive airways was 3.5-fold (P<0.001) enhanced compared to controls. The results indicate that enhanced arginase activity contributes to allergeninduced deficiency of cNOS-derived NO and AHR after the EAR, presumably by competition with cNOS for the common substrate, L-arginine. This is the first demonstration that arginase is involved in the pathophysiology of asthma.
Introduction
Characteristic features of allergic asthma are allergen-induced early (EAR) and late (LAR) asthmatic reactions [1] , infiltration and activation of inflammatory cells in the airways [2] and airway hyperresponsiveness (AHR), both after the EAR and LAR [3] . The mechanisms behind these pathological features are complex and incompletely understood, involving a variety of neurotransmitters, mediators and other signaling molecules, including nitric oxide (NO).
NO is synthesized from the semi-essential amino acid L-arginine both by constitutive (cNOS) and inducible (iNOS) NO synthase isoforms [4, 5] . In the airways, cNOS is mainly expressed in inhibitory nonadrenergic noncholinergic (iNANC) nerves (neuronal NOS or nNOS), endothelial cells (endothelial NOS or eNOS), and airway epithelium (nNOS and eNOS) [6] [7] [8] [9] , and is primarily involved in the regulation of airway and vascular tone by the local production of small amounts of NO in reponse to neurogenic and non-neurogenic stimuli [4] . The involvement of endogenous cNOS-derived NO in the regulation of airway tone is indicated by observations that nonselective NOS inhibitors such as N ω ester (L-NAME) enhanced contractile agonist-induced airway constriction in vitro [10, 11] and in vivo [11] [12] [13] [14] .
iNOS, producing much larger amounts of NO than cNOS, may be induced by pro-inflammatory cytokines during airway inflammation, particularly in inflammatory and epithelial cells [5, 9, 15] , and may be involved in mucosal swelling [16] , infiltration of inflammatory cells [17] and epithelial damage [17, 18] . However, iNOS-derived NO may also have a beneficial bronchodilating action [17, 19] , indicating its dualistic action in the airways.
Several studies in animal models [10, 13, 17, [20] [21] [22] [23] and in asthmatic patients [24] [25] [26] have indicated that a deficiency of cNOS-derived NO may be importantly involved in the pathophysiology of allergic asthma. Using a guinea pig model of allergic asthma, characterized by allergen-induced EAR and LAR, we have established both ex vivo [10] and in vivo [13, 17] that a deficiency of bronchodilating cNOS-derived NO contributes to the AHR observed after the EAR, and that this deficiency is due to limitation of L-arginine as substrate for cNOS [20] .
Different mechanisms could account for this limitation. One mechanism involves inhibition of cellular uptake of L-arginine by specific cationic amino acid transporters induced by polycationic proteins, including eosinophil-derived major basic protein [27, 28] . A second mechanism could be a reduced bioavailability of L-arginine due to enhanced activity of arginase, which hydrolyzes L-arginine to L-ornithine and urea. Arginase, classically an enzyme of the urea cycle in the liver, is also found in many other cells that do not express a complete urea cycle, including the lung [29] . Two distinct isoforms of mammalian arginase -arginase I and II -have been identified [30] , which are constitutively expressed in the airways, particularly in the bronchial epithelium and in peribronchial connective tissue fibroblasts [29] .
The biological function of extrahepatic arginase is largely unclear, but has been implicated in the regulation of NO synthesis and cell growth in inflammatory conditions. In activated macrophages various studies have indicated that arginase activity may limit the utilization of L-arginine by iNOS and suppress the cytotoxic response by these cells [31] [32] [33] , while concomitant polyamine and proline synthesis from L-ornithine may cause cell proliferation and repair of inflammatory lesions [30, 34] . Recent immunohistochemical studies in rat lung indicated that the expression of both arginase I and arginase II in the airways was upregulated during hyperoxic lung injury and recovery. This was associated with reduced NO production and increased expression of ornithine decarboxylase, indicating a role for pulmonary arginase in the repair of hyperoxic lung injury [29] . The role of arginase in asthmatic airway inflammation, however, is presently unknown.
Using a perfused guinea pig tracheal tube preparation, we recently demonstrated that the potent and highly specific arginase inhibitor N ω -hydroxy-nor-Larginine (nor-NOHA) [35] caused a concentration-dependent inhibition of methacholine-induced airway constriction, which was reversed by L-NAME [36] . This indicates that arginase activity in the airways is also involved in the modulation of airway responsiveness, by limiting cNOS-derived bronchodilating NO production. For a number of cells, it has been reported that the expression of arginase may be enhanced by Th2 lymphocyte-derived cytokines such as IL-4, IL-10 and IL-13 and by cAMP-elevating stimuli such as PGE 2 [32, 37, 38] . Since these mediators are crucial in the development of asthmatic airway inflammation [39] , we hypothesized that induction of arginase activity after allergen challenge is involved in the reduction of cNOS activity and the initiation of AHR after the EAR. In the present study, we investigated this hypothesis by examining the effect of the specific arginase inhibitor nor-NOHA on cholinergic AHR in isolated perfused tracheae from sensitized guinea pigs at 6 h after allergen challenge. In addition, we assessed the effect of allergen challenge on arginase activity in these preparations.
Methods

Animals and sensitisation
Outbred specified pathogen free guinea pigs (Harlan, Heathfield, United Kingdom), weighing 600 -800 g, were used in this study. Animals were actively IgE-sensitized to ovalbumin (OA) at 3 weeks of age as described by Van Amsterdam et al. [40] . In short, 0.5 ml of an allergen solution containing 100 µg ml -1 ovalbumin and 100 mg ml -1 Al(OH) 3 in saline was injected intraperitoneally, while another 0.5 ml was divided over seven intracutaneous injection sites in the proximity of lymphe-nodes in the paws, lumbar regions and the neck. The animals were used experimentally in weeks 4 to 8 after sensitization. The animals were group-housed in individual cages in climate controlled animal quarters and given water and food ad libitum, while a 12-h on/ 12-h off light cycle was maintained. All protocols described in this study were approved by the University of Groningen Committee for Animal Experimentation.
Allergen provocation
Ovalbumin provocations were performed by inhalation of aerosolized solutions. The provocations were performed in a specially designed animal cage, in which the guinea-pigs could move freely [41] . The volume of the cage was 9 l, which ensured fast replacement of the air inside the cage with aerosol and vice versa. A DeVilbiss nebulizer (type 646, DeVilbiss, Somerset, PA, USA) driven by an airflow of 8 l min -1 provided the aerosol required, with an output of 0.33 ml min -1 . Allergen provocations were performed by inhalation of an aerosol concentration of 0.05 mg ml -1 ovalbumin in saline. Allergen inhalations were discontinued when the first signs of respiratory distress were observed. Anti-histamines were not needed to prevent the development of anaphylactic shock. Previous studies measuring pleural pressure changes in ovalbumin sensitized, permanently instrumented, unrestrained guinea pigs have indicated that the allergen-induced EAR induced by this procedure is maximal within 20 min and lasts for up to 5 h [41, 42] . Six hours after ovalbumin challenge (between the EAR and LAR; [41, 42] ), the guinea pigs were sacrificed. The animals were killed by a sharp blow on the head and exsanguinated. Nonchallenged animals were used as controls.
Tracheal perfusion
The tracheas were rapidly removed and placed in Krebs-Henseleit (KH) solution (37°C) of the following composition (mM): NaCl 117.50, KCl 5.60, MgSO 4 1.18, CaCl 2 2.50, NaH 2 PO 4 1.28, NaHCO 3 25.00, D-glucose 5.50; gassed with 5% CO 2 and 95% O 2 ; pH 7.4. The tracheas were prepared free of serosal connective tissue and cut into two halves of approximately 17 mm before mounting in a perfusion setup, as described previously [10] . To this aim, the tracheal preparations were attached at each end to stainless steel perfusion tubes fixed in a Delrin perfusion holder. The holder with the trachea was then placed in a water-jacketed organ bath (37°C) containing 20 ml of gassed KH (the serosal or extraluminal (EL) compartment). The lumen was perfused with recirculating KH from a separate 20 ml bath (mucosal or intraluminal (IL) compartment) at a constant flow rate of 12 ml min -1 . Two axially centred side-hole catheters connected with pressure transducers (TC-XX,Viggo-Spectramed B.V., Bilthoven, The Netherlands) were situated at the distal and proximal ends of the trachealis to measure hydrostatic pressures (P outlet and P inlet , respectively). The signals were fed into a differential amplifier to obtain the difference between the two pressures (∆P = P inlet -P outlet ), which was plotted on a flatbed chart recorder (BD 41, Kipp en Zonen, Delft, The Netherlands). ∆P reflects the resistance of the tracheal segment to perfusion and is a function of the mean diameter of the trachea between the pressure taps. The transmural pressure in the trachea was set at 0 cm H 2 O. At the perfusion flow rate used, a baseline ∆P of 0.1 to 1.0 cm H 2 O was measured, depending of the diameter of the preparation. After a 45 min equilibration period with three washes with fresh KH (both IL and EL), 1 µM isoprenaline was added to the EL compartment for maximal smooth muscle relaxation to assess basal tone. After three washes during at least 30 min, the trachea was exposed to EL 40 mM KCl in KH to obtain a receptor-independent reference response. Subsequently, the preparation was washed 4 times with KH during 45 min until basal tone was reached and a cumulative concentration response curve (CCRC) was made with IL methacholine. When used, L-NAME (0.1, 0.5 or 1.0 mM) and nor-NOHA (5 or 10 µM) were applied to the IL reservoir, 40 min prior to agonist-addition.
Arginase assay
Tracheal tissue was snap-frozen in liquid nitrogen and stored at -80°C until homogenization. The tissue was ground using a pestle and mortar in the presence of liquid nitrogen prior to homogenization in approximately 6-vol ice-cold 20 mM Tris HCl, 2 µM phenylmethylsulfonyl fluoride, pH 7.4 using a polytron homogenizer (Kinematica GmbH, Luzern, Switzerland). The homogenate was centrifuged at 20,000 g for 30 min at 4 º C and the supernatant was used for arginase assay. Reactions were terminated by adding 1 ml of ice-cold stop buffer, containing 20 mM sodium acetate, 100 mM urea, 10 mM EDTA and 1 mM L-citrulline, pH 3.0. Samples were applied to columns containing 2 ml Dowex AG 50W-X8 (H + form), preequilibrated with 20 ml of stop buffer. Columns were eluted with stop buffer and aliquots (0.5 ml) were counted in 4 ml Ultima Gold scintillation fluid using a Beckman LS 1701 liquid scintillation counter. The protein concentrations of each sample were determined by the Bradford Coomassie brilliant blue method [44] , using bovine serum albumin as a standard. Arginase activity, expressed as pmol urea.mg protein -1
.min -1 , showed linear enzyme kinetics up to 30 min and was proportional to protein concentration.
Data analysis
To compensate for variations in baseline ∆P and in ∆P responses to contractile stimuli due to variation in resting internal diameter of the preparations used, IL responses of the tracheal tube preparations to methacholine were expressed as a percentage of the response induced by EL administration of 40 mM KCl. The contractile effect of 10 mM methacholine (highest concentration) was defined as E max [10, 20, 28, 36] . Using this E max , the sensitivity to methacholine was evaluated as pEC 50 (-log 10 EC 50 ) value. Kinetic parameters of tracheal arginase activity and its inhibition by nor-NOHA were determined by Lineweaver-Burk analysis, by plotting arginase activity IL perfusion of tracheae from unchallenged control animals with the specific arginase inhibitor nor-NOHA (5 µM) caused a decrease in the E max of methacholineinduced airway constriction by 38 % (P<0.001), while no effect was observed on the pEC 50 value for the agonist ( Figure 1a , Table 1 ). As in a previous study [36] , we demonstrated that the reduced responsiveness in the presence of nor-NOHA can be Unchallenged control 0.1 mM L-NAME 5.0 µM nor-NOHA + 0.1 mM L-NAME + 0.5 mM L-NAME + 1.0 mM L-NAME a A B
Results
In perfused tracheal preparations from unchallenged control guinea pigs, the nonselective NOS inhibitor L-NAME (0.1 mM, IL) caused a significant 1.8-fold increase in the E max of IL methacholine (P<0.01), without an effect on the sensitivity (pEC 50 ) to this agonist ( Figure 1a , Table 1 ). In the ovalbumin-challenged group of animals, the ∆P response to EL KCl was unchanged compared to the unchallenged control group (not shown); however, a 2.0-fold increase in the E max to IL methacholine was observed (P<0.001), without a change in pEC 50 ( Figure 1b , Table 1 ). This increase was not further enhanced in the presence of L-NAME (Figure 1b , Table 1 ).
concentration-dependently reversed by L-NAME, to the level of responsiveness of untreated airways in the presence of the NOS inhibitor ( Figure 1a , Table 1 ). Remarkably, the enhanced E max to IL methacholine at 6 h after allergen challenge was fully restored to the E max value of unchallenged control animals by IL administration of 5 µM nor-NOHA, without an effect on the sensitivity to the agonist; no further effect on E max was obtained in the presence of 10 µM nor-NOHA ( Figure  1b , Table 1 ). The normalized responsiveness in the presence of 5 µM nor-NOHA was completely reversed in the additional presence of 0.1 mM L-NAME (Figure 1b , Table 1 ). Both in the unchallenged control preparations and in the preparations of allergen-challenged animals, L-NAME and nor-NOHA, alone or in combination, had no effect on basal airway tone (not shown). Results are means ± SEM of n experiments. N.D., not determined. Statistical analysis: *P < 0.001; † P < 0.05 compared with unchallenged control; ‡ P < 0.001 compared with OAchallenged control; § P < 0.05 compared with 0.1 mM L-NAME; , respectively; P<0.001). Both in control and in challenged airways 5 µM nor-NOHA caused approximately 95 % inhibition of arginase activity, while the NOS inhibitor L-NAME (0.1 mM) had no effect (Figure 2 ). 
Discussion
The present study demonstrates for the first time the involvement of arginase in the pathophysiology of allergic asthma. Using a guinea pig model of acute allergic asthma, we confirmed our previous finding that the responsiveness of isolated intact tracheal tube preparations to methacholine is considerably enhanced at 6 h after allergen challenge [10] . The allergen-induced AHR was closely mimicked by the administration of L-NAME to unchallenged control preparations, while, in addition, the challenged preparations were unresponsive to the NOS inhibitor, indicating that a deficiency of agonist-induced airway dilating NO is a major determinant of the observed hyperresponsiveness. Remarkably, the enhanced responsiveness to methacholine at 6 h after allergen challenge was fully normalized in the presence of the specific arginase inhibitor nor-NOHA. This indicates that arginase activity, presumably by competition with cNOS for the common substrate, L-arginine, contributes to the deficiency of NO and subsequent AHR after allergen challenge. This hypothesis was confirmed by the observation that the decrease in AHR by nor-NOHA was reversed by administration of L-NAME. As reported in a previous study [36] , endogenous arginase activity is also involved in the regulation of cholinergic airway tone under basal conditions. Thus, IL administration of nor-NOHA also reduced methacholine-induced bronchoconstriction in unchallenged control preparations, which was concentration-dependently reversed by L-NAME, indicating that the reduced airway responsiveness was caused by enhanced production of NO. In the nor-NOHA-treated preparations, a higher concentration of L-NAME (0.5 mM) was required for complete inhibition of the functional antagonism of cholinergic airway constriction by agonist-induced NO than * in untreated controls (0.1 mM), indicating that L-NAME had to compete with a higher concentration of endogenous L-arginine in these preparations.
Since L-arginine is a limiting factor for bronchodilating NO production in the airways [20] , it may be expected that increased arginase activity is involved in the allergen-induced AHR and its inhibition by nor-NOHA as discussed above. Indeed, biochemical measurement of arginase activity in tracheal homogenates indicated that allergen challenge caused a 3.5-fold increase in this activity, which was specifically reversed by 5 µM nor-NOHA, the same concentration as used in the pharmacological experiments. The Nω-hydroxy-L-aminoacid nor-NOHA is one of the most potent arginase inhibitors reported sofar, and the observed Ki value for tracheal homogenates (0.23 µM) corresponds closely to the Ki of 0.5 µM found for purified rat liver arginase [35] .
The sources of NO and constitutive and allergen-induced arginase activity, as well as the arginase isoforms in our perfused tracheal tube preparations were not assessed. Both in control and in challenged airways, L-NAME only increased the agonist-induced constriction and not basal tone, indicating that the NO was most likely produced by cNOS. Previous studies have indicated that agonist-induced bronchodilating NO is mainly derived from the airway epithelium [11] . Since these cells also constitutively express arginase (type I and type II) [29] , it can be hypothesized that the epithelium is an important site of competition between the two enzymes for their common substrate. This may not only apply to the basal condition, but also to the reduced cNOS activity after the allergen challenge. Thus, preliminary data have recently indicated that Th2 cytokines may cause enhanced expression of arginase I and arginase II in cultured A549 human lung epithelial cells [45] . However, it cannot be excluded that other cell types expressing arginase and/or cNOS are involved.
Recently, a role for arginase has also been described in the regulation of inhibitory nonadrenergic noncholinergic (iNANC) nerve-stimulated, cNOS-derived NO-mediated relaxation of the penile corpus cavernosum smooth muscle [46] and the internal anal sfincter smooth muscle [47] . Although iNANC nerve activity was not measured in our tracheal preparations, upregulation of arginase in airway iNANC nerves could also be of importance in allergen-induced airway hyperresponsiveness, since it has been demonstrated that the bronchodilating iNANC activity is reduced after allergen challenge [22] .
Different studies have indicated that the present ex vivo findings are relevant to the development of AHR in vivo. Using the same guinea pig model of asthma, we have recently shown that inhalation of the nonselective NOS inhibitor L-NAME, but not a selective dose of the specific iNOS inhibitor aminoguanidine, caused AHR to histamine before allergen challenge, indicating that cNOS-derived NO counteracts histamine-induced bronchoconstriction under basal conditions [13, 17] . At 6 h after a single allergen challenge, both L-NAME and aminoguanidine had no effect on the allergen-induced AHR to histamine at this time point, indicating that a deficiency of (cNOS-derived) NO contributes to AHR after the EAR [13, 17] , confirming the earlier ex vivo data [10] . A deficiency of cNOS activity and endogenous bronchodilating NO contributing to AHR was also demonstrated after repeated allergen challenge of sensitized guinea pigs [21, 23] . Very interestingly, evidence for a deficiency of cNOSderived NO modulating airway reactivity has also been found in patients with severe asthma treated with corticosteroids, which suppresses the expression of iNOS [24] . Thus, while the airway reactivity to bradykinin (and to methacholine) could be significantly increased by inhalation of NG-monomethyl-L-arginine (L-NMMA) in patients with mild asthma [12] , a similarly enhanced AHR to bradykinin present in severe asthmatics was insensitive to the NOS inhibitor, indicating that a deficiency of NO contributed to the enhanced airway responsiveness in these patients. A recent study by the same authors suggested that this deficiency may indeed be induced by allergen challenge [25] . Accordingly, from the assessment of physical diffusion parameters of NO by measuring the relationship between exhaled NO and expiratory flow, a recent study by Silkoff et al. [26] suggested that residual airway obstruction and AHR in asthmatic patients after steroid therapy are associated with an apparent decrease in activity of cNOS-derived NO.
Our data correspond with a previous observation by Kochańsky et al. [48] , who found two decades ago that arginase activity is enhanced in expectorated sputum from asthmatic patients. The underlying mechanism as well as its functional relevance have thus far not been investigated, but could be related to the allergeninduced increase in arginase activity and AHR found in the present study. Interestingly, in the same study, arginase activity was also shown to be enhanced in patients with chronic bronchitis [48] .
Although speculative, the implications of increased arginase activity in the asthmatic lung could be more widespread. Thus, upregulation of arginase, emerging from Th2 cytokines and other mediators released during allergic airway inflammation, could possibly also limit the synthesis of iNOS-derived-NO known to be present in chronic asthma and to be induced during the LAR [17, 49] , and therefore protect the airways against exaggerated NO production and tissue injury. In addition, as a consequence of increased synthesis of arginase-induced ornithine as a precursor for polyamines and proline, arginase could be involved in the rapid repair process of epithelial damage as observed after allergen challenge in a guinea pig model of acute asthma [50] and in inflammation-induced airway remodeling in chronic asthma [51] , by promoting proliferation of structural subepithelial cells (fibroblasts and airway smooth muscle cells) and collagen deposition. However, the role of arginase in asthmatic airway inflammation and remodeling remains to be established.
The functional inhibition of AHR to methacholine by nor-NOHA in the challenged preparations appeared to be maximal in the presence of 5 µM nor-NOHA, since no additional effect was obtained with 10 µM of the arginase inhibitor. This maximal inhibitory effect did not fully reach the reduced level of responsiveness observed in the control preparations in the presence of nor-NOHA, indicating that additional mechanisms may be involved in the development of the allergen-induced NO deficiency and AHR. One of these mechanisms could be limitation of L-arginine by reduced cellular uptake of this aminoacid, induced by inhibition of specific cationic amino acid transporters by polycations such as eosinophil-derived major basic protein [27, 28] . As in humans, eosinophilic polycations have been demonstrated in the inflamed guinea pig airways at 6 h after allergen challenge [52] .
In conclusion, using a guinea pig model of allergic asthma we have established that enhanced arginase activity may be importantly involved in the allergen-induced NO deficiency and AHR after the EAR, presumbly by competition with cNOS for the common substrate, L-arginine. Since reduced cNOS-derived bronchodilating NO has also been recognized to contribute to AHR in asthmatics patients, the advent of new and selective arginase inhibitors could have therapeutic potential in allergic asthma. However, since enhanced bioavailability of L-arginine may also amplify the inflammatory effects of iNOS-derived NO present in most patients [53] , their usefulness remains to be established.
